CARsgen Therapeutics Receives IND Clearance for GPC3-CAR-T Cells from the NMPA
SHANGHAI, Jan. 29, 2019 /PRNewswire/ — CARsgen Therapeutics, a clinical-stage company committed to developing Chimeric Antigen Receptor T cell therapies for cancer, today announced that one of its leading drug…